Texas Oncology, P.A. Texas Oncology - Sammons
Welcome,         Profile    Billing    Logout  
 5 Trials 
9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Becerra, Carlos
NCT04121442: Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Completed
1/2
15
US
Isunakinra, EBI-005, PD-(L)1 Inhibitor
Buzzard Pharmaceuticals, Baylor Research Institute
Solid Tumor, Adult
12/23
07/24
NCT02744287: Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Feb 2023 - Feb 2023: Early P1 data in patients with metastatic castration-resistant prostate cancer at ASCO-GU 2023
Checkmark Updated data from BP-012 trial
Oct 2020 - Oct 2020: Updated data from BP-012 trial
Checkmark From BP-012 trial in advanced solid tumors at ASCO 2019 [screenshot]
May 2019 - Jun 2019: From BP-012 trial in advanced solid tumors at ASCO 2019 [screenshot]
More
Suspended
1/2
151
US
BPX-601, Rimiducid, AP1903
Bellicum Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
10/25
02/26
NCT04834778: A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

Completed
1
23
US
HC-5404-FU, HC-5404
HiberCell, Inc., Covance
Renal Cell Carcinoma, Gastric Cancer, Metastatic Breast Cancer, Small-cell Lung Cancer, Other Solid Tumors
12/23
01/24
NCT06130722: First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Recruiting
1
18
US
FL115
Suzhou Forlong Biotechnology Co.,Ltd,
Locally Advanced/Metastatic Solid Tumors
05/25
09/25
NCT06218914: A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Recruiting
1
24
US
NT-112: Autologous, engineered T Cells targeting KRAS G12D
AstraZeneca
Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D
08/27
08/40
KEYNOTE-E46, NCT06125197: Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Recruiting
1
22
US
TILT-123, Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123), KEYTRUDA®, pembrolizumab, pembrolizumab (MK-3475)
TILT Biotherapeutics Ltd., Merck Sharp & Dohme LLC
Lung Cancer
01/26
05/26
SGNTGT-001, NCT04254107: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated
1
132
Europe, Canada, US
SEA-TGT, SGN-TGT, sasanlimab, brentuximab vedotin, Adcetris
Seagen Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
12/23
12/23
INDP-D101, NCT05651022: DECOY20 Study in Patients with Advanced Solid Tumors

Recruiting
1
120
US
Decoy20
Indaptus Therapeutics, Inc, Translational Drug Development
Solid Tumor, Adult
06/27
09/27
NCT05948865: A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

Recruiting
1
102
Canada, US
CPO301, SYS6010
Conjupro Biotherapeutics, Inc.
Cancer, Cancer, Lung
06/25
12/25

Download Options